(NASDAQ: PCVX) Vaxcyte's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.61%.
Vaxcyte's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast PCVX's revenue for 2026 to be $16,741,450,650, with the lowest PCVX revenue forecast at $16,741,450,650, and the highest PCVX revenue forecast at $16,741,450,650. On average, 1 Wall Street analysts forecast PCVX's revenue for 2027 to be $1,596,018,295, with the lowest PCVX revenue forecast at $1,596,018,295, and the highest PCVX revenue forecast at $1,596,018,295.
In 2028, PCVX is forecast to generate $14,849,666,727 in revenue, with the lowest revenue forecast at $1,596,018,295 and the highest revenue forecast at $28,103,315,158.